Growth Direct System Consumables
Archived on July 29, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 11:00 AM EDT
- Posted
- June 29, 2026
- Notice type
- Sources Sought
- Set-aside
- No Set aside used
- NAICS
- 334516: Analytical Laboratory Instrument Manufacturing
- Agency
- Department of WarDEFENSE HEALTH AGENCY (DHA)
Notice details
- Office
- DEFENSE HEALTH AGENCY
- Place of performance
- Silver Spring, Maryland, 20910
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- HT9426-26-RFI-0836
- Notice ID
- 7bb540cbafb44070b12ad4c77cda4462
Description
This Request for Information (RFI)/Sources Sought (SS) Notice is for the market research information and planning purposes only, and shall not be construed as a solicitation or as an obligation on the part of Walter Reed Army Institute of Research (WRAIR) Center for Enabling Capabilities' (CEC) Pilot Bioproduction Facility (PBF), or the Defense Health Agency Contracting Activity (DHACA).
This is a requirement to establish a single award Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle that will allow the Center for Enabling Capabilities' (CEC) Pilot Bioproduction Facility (PBF) to procure the proprietary consumables required for the Government-owned Growth Direct™ System currently used by the PBF.
See attached request for information with minimal essential characteristics.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Files (1)
- Download
RFI - Growth Direct System Consumables.pdf
147 KBAdded in Sources Sought version 3Posted
Lifecycle
- 3Version 3Sources SoughtArchivedCurrent
Growth Direct System Consumables
- 6Version 6Special NoticeArchived
Type changed from Sources Sought to Special Notice
Growth Direct System Consumables
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Simplified Acquisition: NAREL consumables | 77% | Awarded | Open |
Answers to Questions attached. Questions are due by 11:00 AM Monday, 16 November 2026. The proposal due date has not been extended. | 74% | Solicitation | 11/23/2026 |
The Defense Health Agency Contracting Activity (DHACA) intends to award a Firm Fixed Price, sole source Contract on behalf of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to DNA Script Inc, located in Cambridge, MA, under the authority of 41 U.S.C. 1901, as prescribed in RFO FAR 12.102(b) Restricting Competition for acquisitions valued over the SAT. This requirement is for the acquisition of 1 benchtop DNA synthesizer system with a preventative maintenance support contract for an additional 4 years. The benchtop unit shall meet the following minimum essential characteristics: 1. The synthesizer table-top dimensions must not exceed: 48’’ x 26’’ x 29’’. The required vacuum cabinet (freestanding) is 33’’ x 26’’ x 26’’ (inches). 2. The synthesizer shall have same-day throughput e.g. 96 oligos of 20 nucleotides in length in approximately 6 hours and 120 nucleotides in less than 24 hours 3. The synthesizer shall synthesize oligos labeled with fluorophores, quenchers, or biotin with the use of appropriate reagent kits with up to 5 colors in parallel. 4. The synthesizer shall be fully automated: oligos are synthesized, quantified, and normalized in a single synthesis run without user interaction following an approximate range of 15 to 30 minutes of setup. 5. The synthesizer shall have console software that can be installed and hosted on a stand-alone, off-network computer connected to the synthesizer. 6. The synthesizer shall have no harsh organic solvents: the product uses biochemistry, composed of water-based reagents, proprietary enzymes, and proprietary nucleotides that are typically compliant with standard laboratory waste management systems. 7. The synthesizer can perform without any specific environmental control (no need for Argon or any Gas). 8. The synthesizer should have an output power capacity of 1800 W / 2200 VA, 120 VAC input/output voltage and NEMA 5-20P input connection. 9. The synthesizer should produce oligos as they occur in biology, producing oligos that are free of molecular defects or blemishes. 10. The data management software shall provide user authentication features to include: password complexity requirements; automatic logout; limited login attempts; and account inactivity period. 11. The data management software shall have full traceability for synthesis runs, quality control runs, instrument maintenance, reagent usage, user identification, and 5 years of support. 12. The synthesizer shall permit data export to a backup medium. 13. The contractor shall provide method validation services and on-site and off-site operator training, as well as on-site start up support. 14. The contractor shall provide onsite preventative and corrective maintenance for analyzers previously used in biocontainment laboratories (following decontamination). 15. The contractor shall be an Original Equipment Manufacturer (OEM) authorized dealer, authorized distributor, or authorized reseller for the quoted equipment such that OEM warranty and service are provided and maintained by the OEM. All software licensing, warranty, and services associated with the equipment shall be in accordance with OEM terms and conditions. DNA Script is the only vendor who has a benchtop DNA synthesizer capable of producing 96 oligonucleotides of 20 nucleotides in lengths in 6 hours and 120 nucleotides in length in 24 hours. DNA Script also has the capability of adding biotin, quenchers, and fluorescent molecules to the oligonucleotides for downstream applications, reducing the cost of targeting pathogens. DNA Script’s synthesizer is the only unit capable of meeting all the government’s minimum essential characteristics. The safety features built into the synthesizer protect users by reducing the use of hazardous chemicals, dedicated fume vents, and gas cylinders limiting exposer to stored chemicals. This announcement fulfills the synopsis requirement under RFO FAR 5.101(a). This notice of intent is NOT a request for quotations (RFQ) and no solicitation document exists for the requirement; however, if a vendor challenges the basis for this requirement, please submit a capability statement that includes sufficient detail and with convincing evidence that clearly demonstrates the capability to meet the governments requirement. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source procurement. Any other firms desiring consideration must submit capability statements and identify their interest and capability in providing these services. Responses to this notice must be received no later than 0900 Eastern Time, 2 November 2026. Capability statements shall be submitted via email ONLY as a Microsoft Word or Adobe PDF attachment to the following email addresses ryan.r.jorgensen.civ@health.mil and jayme.l.fletcher2.civ@health.mil. No phone calls will be accepted. | 74% | Special Notice | 11/02/2026 |
1. Disclaimer THIS IS A SOURCES SOUGHT NOTICE ONLY. This notice is issued solely for information and market research planning purposes. It does not constitute a Request for Quotation (RFQ), Request for Proposal (RFP), or Invitation for Bids (IFB), nor does it restrict the Government to a particular acquisition approach. No contract or purchase order will be awarded from this announcement, and the Government will not reimburse respondents for any costs incurred in preparing a response. 2. Background and Purpose The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions,, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Section of Cell Cycle Regulation, has a requirement for a Brand-Name Lonza 4D-Nucleofector® System consisting of the following: 4D-Nucleofector Core Unit, Part No. AAF-1003B – Quantity (1) EA 4D-Nucleofector X Unit, Part No. AAF-1003X - Quantity (1) EA 3. One-year warranty extension for each unit. Or a functional domestic equivalent, to support ongoing NIH-funded research involving the genetic manipulation of mammalian cells. Because NICHD's ongoing studies rely on previously validated electroporation pulse-code workflows, experimental protocols, and Nucleocuvette™ consumables established on a prior-generation Lonza Nucleofector platform, the Lonza 4D-Nucleofector® System is the primary known platform capable of ensuring experimental reproducibility and data continuity without requiring costly and time-consuming protocol re-optimization or re-validation. The Office of Acquisitions is conducting market research to identify qualified vendors—including small businesses, authorized distributors, and domestic manufacturers—and specifically seeks market information to determine: 1. Authorized Lonza Sources: The availability of Lonza Walkersville, Inc. or authorized distributors/resellers (including small businesses, HUBZone, 8(a), SDVOSB, WOSB, and Small Disadvantaged Businesses under NAICS 334516) capable of supplying new Lonza equipment with full manufacturer-backed warranties. 2. Buy American Act (FAR Part 25) Compliance: The availability of any domestic end products manufactured in the United States capable of meeting all functional, warranty, training, and legacy workflow-continuity requirements outlined in Section 3 without requiring experimental re-validation. 3. Technical Requirements and Salient Characteristics To meet the Government's minimum requirements, the proposed system must satisfy all functional and technical specifications from the Statement of Work alongside the laboratory's workflow-continuity constraints: Core Control Unit: The system shall include a Lonza 4D-Nucleofector® Core Unit (or a domestic equivalent central control unit) capable of controlling and operating advanced electroporation-based transfection protocols. Small-Volume Transfection Module: The system shall include a Lonza 4D-Nucleofector® X Unit (or a domestic equivalent functional module) capable of processing small-volume samples (specifically ranging from 20 µL to 100 µL) and supporting transfection of primary cells and other difficult-to-transfect cell types. Nucleic Acid & Reagent Delivery: The system shall support delivery of plasmid DNA, RNA, siRNA, CRISPR/Cas9 reagents, and other nucleic acid-based materials into mammalian cells. Optimized Transfection Performance: The system shall provide optimized electroporation programs designed to maximize transfection efficiency while maintaining high post-transfection cell viability. Sensitive Cell Applications: The system shall support research applications involving primary cells, stem cells, immune cells, and other sensitive cell populations that are not efficiently transfected using conventional lipid-based methods. Software and Protocols: The system shall include manufacturer-provided software and protocols necessary for operation of the instrument. Warranty Coverage: The system shall include a minimum one-year manufacturer warranty and one-year warranty extension coverage for both the Core Unit and X Unit (two years total coverage). Warranty coverage shall begin upon Government acceptance of the equipment and continue in accordance with the manufacturer's warranty terms. Consumable & Legacy Protocol Continuity: If proposing Lonza equipment, the system shall be 100% compatible with commercially available Lonza Nucleofector® reagents, Nucleocuvette™ consumables, and existing pulse-code workflows previously developed and validated on a prior-generation Lonza Nucleofector platform. If proposing a domestic alternative, the vendor must demonstrate that its system and consumables achieve equivalent transfection efficiency and post-transfection cell viability across NICHD's existing mammalian cell workflows without requiring protocol re-optimization or experimental re-validation. Delivery, Installation, and Training: Equipment must be delivered to NIH Bethesda (Building 49) and installed, with on-site or virtual user training for up to five (5) NIH personnel completed within 30 days of installation (covering system operation, software functionality, routine maintenance, and basic troubleshooting). All delivery, installation, and training shall be completed within the 12-month period of performance from award. 4. Capability Statement Submission Instructions Interested organizations that believe they can meet all requirements outlined in Section 3 are invited to submit a tailored Capability Statement (no more than 5 pages) containing the following information: 1. Company Profile: Organization name, mailing address, primary Point of Contact (name, title, email, and telephone number), SAM.gov Unique Entity ID (UEI), and CAGE code. 2. Business Size & Socioeconomic Status: Business size under NAICS 334516 (1,000-employee size standard) and applicable socioeconomic designations (e.g., Small Business, Woman-Owned, Veteran-Owned, Service-Disabled Veteran-Owned, HUBZone, 8(a)). 3. Contract Vehicles: Identification of any existing federal contract vehicles held by the vendor through which this equipment can be ordered (e.g., GSA Multiple Award Schedule), or confirmation of open-market availability. 4. Country of Origin (COO): Explicit identification of the manufacturing country of origin for all proposed hardware components and confirmation of whether the system qualifies as a domestic end product under the Buy American Act (FAR Part 25). 5. Technical Capability & Authorization: Product brochures, technical specifications, and catalog numbers demonstrating compliance with every requirement in Section 3. If proposing Lonza equipment: Documentation confirming status as an Authorized Distributor/Reseller eligible to provide new equipment and manufacturer-backed warranties. If proposing a domestic alternative: Technical evidence proving equivalent transfection performance and workflow continuity with existing NICHD mammalian cell protocols without requiring experimental re-validation. 6. Rough Order of Magnitude (ROM) Pricing (Optional): Non-binding budgetary pricing estimate for market research purposes. 5. Place of Performance: NIH, 9000 Rockville Pike, Bethesda, MD 20892 6. Submission Deadline and Contact Information Please submit electronic Capability Statements in PDF or Microsoft Word format via email to Tina Robinson at robinsti@mail.nih.gov no later than November 18, 2026, at 11:00 AM EST. Telephone inquiries will not be accepted. Capability Statements must reference Notice Number 75N98027R00019. Email submissions and any questions must be sent to robinsti@mail.nih.gov and include Notice Number 75N98027R00019 in the subject line. Capability Statements and attachments will not be returned to the sender. This synopsis is for information and planning purposes only and shall not be construed as a commitment by the Government, nor will the Government pay for information solicited. | 72% | Market Research | 11/18/2026 |
71% | Awarded | Open |
Additional Details
Solicitation Number
HT9426-26-RFI-0836
Archive Date
Jul 29, 2026
Office Address
FORT DETRICK, MD, 21702